
Impact of *Demodex* Blepharitis on Patients and the Healthcare System: Results from the Atlas Continuation Study

Presented at ARVO 2022


Authors

Blake Simmons, OD; Patrick Vollmer, OD; William Whitson, MD; Gregg Berdy, MD; Mark Holdbrook; Stephanie Baba, OD; John Meyer, MD



FINDINGS

See the graphs below that highlight Demodex blepharitis patients' symptoms, motivation to seek care, and impact on daily life.



Proper *Demodex* blepharitis diagnosis with an FDA-approved treatment that is **safe**, **tolerable**, and **effective** is needed for eyecare patients to address and improve their symptoms and quality of life.

Of patients who discontinued

their regimen, discontinued due to

ineffectiveness or tolerability issues